Skip to content

Study · Randomized controlled trial · n = 701 · 2022

5 results

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.

Yabe D, Deenadayalan S, Horio H, Kaneto H, Jensen TB, Terauchi Y, Yamada Y, Inagaki N

Journal of diabetes investigation3 Mar 2022Cited by 22 (Europe PMC)

PMID35112504 (opens in a new tab)PMCIDPMC9153832 (opens in a new tab)DOI10.1111/jdi.13764 (opens in a new tab)PepBankPUB-35112504
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes, HbA1c reductions with oral semaglutide increased as baseline HbA1c increased in both PIONEER 9 and 10.

    In plain wordsIn Japanese adults with type 2 diabetes, oral semaglutide lowered HbA1c more in people whose starting HbA1c was higher.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction by baseline HbA1c
    Study

    n = 701

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3, 7 or 14 mg · oral · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    In both trials, HbA1c reductions increased as baseline HbA1c increased
    2 context sentences
    Summary · context
    In the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) 9 and 10 trials, Japanese patients were randomized to once-daily oral semaglutide (3, 7, or 14 mg) or a comparator (placebo or once-daily subcutaneous liraglutide 0.9 mg in PIONEER 9; once-weekly subcutaneous dulaglutide 0.75 mg in PIO…
    Summary · context
    An exploratory analysis grouped patients in each trial according to baseline glycated hemoglobin (HbA1c ; ≤8.0, >8.0-≤9.0, or >9.0%), body mass index (2 ) and, for PIONEER 10 only, by background medication (sulfonylurea, glinide, thiazolidinedione, α-gl…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes, no other pattern appeared between the baseline variables studied and HbA1c change with oral semaglutide.

    In plain wordsIn Japanese adults with type 2 diabetes, no other starting factor clearly changed how much oral semaglutide lowered HbA1c.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c change by baseline BMI and background medication
    Study

    n = 701

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3, 7 or 14 mg · oral · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    there were no other apparent patterns between the variables investigated and HbA1c or bodyweight changes.
    2 context sentences
    Summary · context
    In the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) 9 and 10 trials, Japanese patients were randomized to once-daily oral semaglutide (3, 7, or 14 mg) or a comparator (placebo or once-daily subcutaneous liraglutide 0.9 mg in PIONEER 9; once-weekly subcutaneous dulaglutide 0.75 mg in PIO…
    Summary · context
    An exploratory analysis grouped patients in each trial according to baseline glycated hemoglobin (HbA1c ; ≤8.0, >8.0-≤9.0, or >9.0%), body mass index (2 ) and, for PIONEER 10 only, by background medication (sulfonylurea, glinide, thiazolidinedione, α-gl…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes, no apparent pattern appeared between the baseline variables studied and bodyweight change with oral semaglutide.

    In plain wordsIn Japanese adults with type 2 diabetes, no starting factor clearly changed how much weight people lost on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeBodyweight change by baseline variables
    Study

    n = 701

    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3, 7 or 14 mg · oral · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    there were no other apparent patterns between the variables investigated and HbA1c or bodyweight changes.
    2 context sentences
    Summary · context
    In the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) 9 and 10 trials, Japanese patients were randomized to once-daily oral semaglutide (3, 7, or 14 mg) or a comparator (placebo or once-daily subcutaneous liraglutide 0.9 mg in PIONEER 9; once-weekly subcutaneous dulaglutide 0.75 mg in PIO…
    Summary · context
    An exploratory analysis grouped patients in each trial according to baseline glycated hemoglobin (HbA1c ; ≤8.0, >8.0-≤9.0, or >9.0%), body mass index (2 ) and, for PIONEER 10 only, by background medication (sulfonylurea, glinide, thiazolidinedione, α-gl…
  4. 04HumanRandomized controlled trialSafety outcome

    In Japanese adults with type 2 diabetes, baseline HbA1c, BMI and background medication did not appear to affect the proportion of patients reporting adverse events with oral semaglutide.

    In plain wordsIn Japanese adults with type 2 diabetes, starting HbA1c, weight and other medicines did not seem to change how many people reported side effects.

    Peptide
    Semaglutide
    Outcome
    No significant changeProportion of patients with adverse events by baseline HbA1c, BMI and background medication
    Study

    n = 701

    Analysis
    Exploratory
    Outcome group
    Adverse events · Whole body
    Studied dose
    3, 7 or 14 mg · oral · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Baseline HbA1c , baseline body mass index and background medication did not appear to affect the proportions of patients reporting adverse events.
    2 context sentences
    Summary · context
    In the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) 9 and 10 trials, Japanese patients were randomized to once-daily oral semaglutide (3, 7, or 14 mg) or a comparator (placebo or once-daily subcutaneous liraglutide 0.9 mg in PIONEER 9; once-weekly subcutaneous dulaglutide 0.75 mg in PIO…
    Summary · context
    An exploratory analysis grouped patients in each trial according to baseline glycated hemoglobin (HbA1c ; ≤8.0, >8.0-≤9.0, or >9.0%), body mass index (2 ) and, for PIONEER 10 only, by background medication (sulfonylurea, glinide, thiazolidinedione, α-gl…
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes in PIONEER 9, one statistically significant interaction was found between baseline HbA1c and the treatment difference in bodyweight change for oral semaglutide 14 mg versus placebo.

    In plain wordsIn Japanese adults with type 2 diabetes, starting HbA1c was linked to the weight change difference between semaglutide 14 mg and placebo.

    Peptide
    Semaglutide
    Outcome
    Not applicableInteraction of baseline HbA1c with bodyweight change, oral semaglutide 14 mg versus placebo (PIONEER 9)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    14 mg · oral · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    There was one statistically significant subgroup interaction between baseline HbA1c and estimated treatment differences in bodyweight change for oral semaglutide 14 mg versus placebo in PIONEER 9 (P = 0.0286).
    2 context sentences
    Summary · context
    In the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) 9 and 10 trials, Japanese patients were randomized to once-daily oral semaglutide (3, 7, or 14 mg) or a comparator (placebo or once-daily subcutaneous liraglutide 0.9 mg in PIONEER 9; once-weekly subcutaneous dulaglutide 0.75 mg in PIO…
    Summary · context
    An exploratory analysis grouped patients in each trial according to baseline glycated hemoglobin (HbA1c ; ≤8.0, >8.0-≤9.0, or >9.0%), body mass index (2 ) and, for PIONEER 10 only, by background medication (sulfonylurea, glinide, thiazolidinedione, α-gl…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 5 to 10Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 4

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 3

    12 Oct 2026, 11:11 UTC

    Study results updated

  4. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  5. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.